P/E ratio for Eagle Pharmaceuticals (EGRX)
P/E ratio as of April 2024 (TTM): 4.43
According to Eagle Pharmaceuticals 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 4.43478. At the end of 2022 the company had a P/E ratio of 10.4.
P/E ratio history for Eagle Pharmaceuticals from 2014 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 10.4 | -113.43% |
| 2021 | -77.2 | -247.44% |
| 2020 | 52.3 | -10.29% |
| 2019 | 58.3 | 215.61% |
| 2018 | 18.5 | 19.01% |
| 2017 | 15.5 | 3.74% |
| 2016 | 15.0 | -95.27% |
| 2015 | 317 | -3389.37% |
| 2014 | -9.63 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 10.4 | 134.44% | 🇺🇸 USA |
 Novartis NVS | 26.2 | 490.86% | 🇨🇭 Switzerland |
 Eli Lilly LLY | 135 | 2,950.28% | 🇺🇸 USA |
 Amgen AMGN | 19.1 | 329.56% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 11.4 | 156.53% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 11.7 | 164.38% | 🇬🇧 UK |
 Teva Pharmaceutical Industries TEVA | -6.75 | -252.15% | 🇮🇱 Israel |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.